Questcor Pharmaceuticals, Inc. (QCOR)

[philca]

Looks good for me....up to the reports.

[Its A Whiz]

From the scripts it looks like they will beat with .80-84 per share. My best guess.

[philca]

I'm curious what the third quarter results will bring on october the 23. Anyone a suggestion?????

[pj McMulligan]

Beautiful pincher expansion occurring on QCOR with bullish SAR flip~ Who here is adding more shares with the middle Bollinger Band breakout today?

[shankapotamus]

That's a very reasonable target

[lifter]

congrats to those who got in near bottom and are up big on on this or already took profits

[philca]

For me the same....i repeat my target will be 28$.

[shankapotamus]

Okay!

[Its A Whiz]

Yep, This thing has legs. You can tell that the squeeze is coming by the charts and the posts claiming they are selling or pulling profits because it has run its course. I would not be selling this until the run goes to at least $40. I can not believe someone would sell right after the stock goes over a gap fill trigger. Its like having a Filet Mignon in front and your starving so you eat half, and leave the rest to the trash. I would change my opinion if QCOR was laden with debt. Or if I felt that the 57 mil shares outstanding was being diluted by the 7 mil share buyback. Or even if the Sept scripts were poor. Well you get the picture.

[Its A Whiz]

Do your own DD. People were laughing when Apple was trading at 70 also. Here's a hint. Next years Earnings per share and industry average earnings multiple. If you don't get it, well I understand. No emotional loss for me. LMAO

[philca]

Looks good...

[shankapotamus]

80-100? Lmao.

[Its A Whiz]

Congrats Shank
To Everyone,
Analyzing the chart, gap up when the stock closes above 22.70, next levels will be at 25.50 then 27.90 then some resistance about 30.
Also tonight Deerfield Hedge Fund has disclosed in their 13G that they now own a little more then 5% of QCOR. This is a new long position. Brings a new bit of confidence to the picture.

Could be a gap up tomorrow. Some talk about 30%. Could be more then $30 by end of week. It is common opinion that Deerfield disclosure will drive additional Institutional buying. If their position expands there is even more talk of possible buyout offer in the area of 80-100. Eyes will be on the kidney week conference where Questcor will present to over 13k Doctors the benefits of Acthar use with Kidney diseases. GLTA Hold them tight, next few days should make you smile more then you did all last week.

[shankapotamus]

GL! I'm happy with +20%. I'll buy back on a retrace and compound it.

[pj McMulligan]

I'm holding my shares tight buddy, this one going higher before it goes lower imo! B~)

[philca]

Questcor to Report Third Quarter Results on October 23, 2012
7:00a ET October 15, 2012 (PR NewsWire) Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2012 financial results on Tuesday, October 23, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 23, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments. The call can be accessed in the following ways:

By webcast: At Questcor's investor relations website: http://ir.questcor.com/.

By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is [phone]. For participants outside the U.S., the dial-in number is [phone].

By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call. The dial-in number for U.S. participants is [phone]. For participants outside the U.S., the replay dial-in number is [phone]. The replay access code for all callers is 39696380.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

[philca]

I"m still waiting....my target is 28$...we're still going up...

[shankapotamus]

Took profits at 22.99. Waiting to re-enter.

[lifter]

cool hope you make some $$$

[shankapotamus]

$QCOR chart and opinion: http://blog.chartmystock.com/2012/10/14/qcor-questcor-pharmaceuticals.aspx

[shankapotamus]

"You're" welcome to hold as long as you like. My target is $25. If it goes higher, I'm fine with that. GLTA

[Its A Whiz]

What are you saying about Earnings now that they released scripts for Sept. Hope you covered. Too much upside coming.

[Its A Whiz]

Your too low, 5 Bullish Signs since the 5th. Last was Friday WilliamsR% Bullish, Thursday RSI went Bullish, Wednesday MACD Crossed Bullish. Shorts have not covered. Gap fill up to $30. Some say it will start to occur at 22.70.

[philca]

Hey lifter,

i didn't play the bounce...i've got time

[philca]

I'm also thinking this will be easy money...we're going every day a little up...my target is 28$...and i think it won't take long ....

[shankapotamus]

By the divy ex date, I hope.

[elbiatcho1]

$25 is my short term target.

How short term is that? 1 week from now?
Its already at 22.

[shankapotamus]

This stock is easy money IMO. $25 is my short term target.

[lifter]

no clue on future just play the bounce

they did just get an upgrade from jeffries

[philca]

S omeone still in? What are you expecting from qcor for the future?

[lifter]

ahhh nice little bounce 3.5% move

[lifter]

nice little bounce then back to red, I missed it at work on watch

[shankapotamus]

Sweet. That should attract some institutional buying IMO.

[elbiatcho1]

2012-09-28 - Questcor Pharmaceuticals Initiates Quarterly Cash Dividend and Expands Stock Repurchase Program

ANAHEIM, Calif., Sept. 28, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (QCOR) today announced that its Board of Directors has adopted a policy to pay a regular quarterly dividend in such amounts as the Board of Directors may determine from time to time. The Board of Directors has declared an initial quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on October 31, 2012. The initial dividend will be paid on or about November 15, 2012. Future dividends will be at the discretion of the Board of Directors.

Questcor also announced that its Board of Directors has increased the Company's common stock repurchase program to 7 million shares. This includes the 3.2 million shares that were remaining under the prior authorization. Repurchases under the program may be made in the open market or in privately negotiated transactions from time to time in compliance with Securities and Exchange Commission regulations, depending on market conditions and other factors.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

Our reliance on Acthar for substantially all of our net sales and profits;
Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with Nephrotic Syndrome, and our ability to develop other therapeutic uses for Acthar;
Research and development risks and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results;
Our ability to receive high reimbursement levels from third party payers;
Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices;
Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
Our ability to effectively manage our growth, including the expansion of our sales force, and our reliance on key personnel;
Volatility in Questcor's monthly and quarterly Acthar shipments, estimated channel inventory, and end-user demand, as well as volatility in our stock price; and
Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.

For more information, please visit www.questcor.com or www.acthar.com.

http://finance.yahoo.com/news/questcor-pharmaceuticals-initiates-quarterly-cash-123000423.html

[Nebuchadnezzar]

if the entire market sells off, i hardly think QCOR will go up. very few stocks go up when the market tanks during correction periods. usually money is just shifting, perhaps a heavily shorted stock may rise due to short covering so that money can flow into other plays, LONG OR SHORT. A stock with investigations will not bode well regardless of the market. this thing can still head to single digits.

i think a major correction is coming. if earnings disappoint, watch out

[lifter]

I hope i can get on this tommorrow before a big bounce

[sgray74]

It's not the shorts.....the whole market is going down...it will go up with the market....if and when the market decides to go up

[TOXX]

Shorts got there claws deep in this one.

[lifter]

alot of free advertising going on, If I owned a lawfirm I would launch an investigation as well.

[HadMint1]

QCOR has many things going for it in the long term, however this stock is short controlled right now. Eventually the shorts will overstay their welcome and this stock will head higher. When that happens I don't think that it unheard of for it to hit the low end of analysts price target of $26. This stock is very oversold and should hit $22 once it hits the 30 RSI so if you bought down here don't worry as I think that a marginal bounce is in the cards. What they need is some positive news IMO.

[stocky101]

This game is tigged

[stocky101]

Agree

[shankapotamus]

This stock has no idea where it wants to go. Lol

[stocky101]

Setting up nicely @ $20

[shankapotamus]

I'll happily unload at $25.

[stocky101]

$26 call on this gem!!!! Hold tight.... Could head back to $24-$25 today!!!!!

[shankapotamus]

The shorts made a nice return on this one. No doubts! Maybe they've covered and moved on by now.

[lmfao1234]

Thinking, this has a major bounce coming for it. The investigation will take considerable time and as long as other health insurers dont go running away from this company in the next couple days, this should bounce very nicely. Its the unfortunate effect of having a stock that is already on the decline get hit with added negative news feeds. They tend to drop way worse than they should. Should be a good trade here in the next couple days for those playing the bounce. This thing is way oversold. jmo.

[stocky101]

Still a $47 Price Target on QCOR, updated by the analyst today!!!!!!

[shankapotamus]

Ouch. I feel lucky for selling last Thursday. Was kicking myself all weekend because it went back up Friday though. I bought some back at 20.10 today thinking it would bounce. Hopefully it will reverse.